Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Next-Generation TIL
- Development stage
- Preclinical
- Lead developer
- Obsidian Therapeutics
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Next-Generation TIL is a preclinical-stage cell therapy program being developed by Obsidian Therapeutics. The program focuses on engineering tumor-infiltrating lymphocytes (TILs) using the proprietary cytoDRiVE platform to enhance their therapeutic potential. While specific targets for this program are currently undisclosed, the technology enables the pharmacologically regulated expression of therapeutic proteins—such as cytokines or costimulatory ligands—within the TILs. This approach is designed to improve the expansion, persistence, and anti-tumor potency of the cells within the immunosuppressive tumor microenvironment, potentially eliminating the need for high-dose systemic interleukin-2 (IL-2) support. The program is distinct from the company's lead candidate, OBX-115, and is being evaluated for undisclosed oncology indications.
- Other names
- Next-Generation TIL
Beyond the preview
Go deeper on Next-Generation TIL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Next-Generation TIL.